Metabolic Restoration Insights You Need to Reduce Insulin Resistance

Discover how metabolic restoration can reduce insulin resistance and improve health and metabolic balance.

Insulin Resistance, Retatrutide, and Integrative Care Strategies

As a practitioner dedicated to understanding the web of human health, I am Dr. Alex Jimenez. My credentials span several disciplines: Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), and board-certified Family Nurse Practitioner (FNP-BC), Certified Functional Medicine Practitioner (CFMP, IFMCP), Advanced TBI Nutritionist (ATN), and specialist in Cranial Cervical Spinal Technology (CCST). The mission that ties those licenses together is simple. Find and treat the root drivers of chronic illness. Do not stop at the downstream label.

At Injury Medical Clinic PA in El Paso, Texas, that mission is a team sport. I work alongside Dr. Maria Guadalupe Cardenas, MD, a board-certified internist with more than 40 years of experience. As Medical Director and Collaborative Physician (Texas MD License #J2933, NPI #1164426749), Dr. Cardenas provides medical oversight that lets chiropractic care, functional medicine, personal-injury rehabilitation, and internal medicine sit under one roof. Patients do not get a back plan in one building and a blood-sugar plan in another. They get one coordinated strategy.

This educational post is a deep look at insulin resistance as the upstream “source code” of many of the most common—and most expensive—chronic diseases of our time. We will review how hyperinsulinemia quietly programs type 2 diabetes, fatty liver disease, cardiovascular disease, and neurodegeneration. We will look at what investigational triple-agonist medicines such as retatrutide actually show in peer-reviewed trials. We will be honest about access, pricing, and the tension between reversing metabolic disease and managing it for decades. Most of all, we will spend real time on a question patients in El Paso ask every week: what does the spine and nervous system have to do with insulin, belly fat, and energy? The short answer is more than most people were ever told.

The Upstream Source Code: Unmasking Insulin Resistance as the Genesis of Chronic Disease

Modern chronic disease looks like a collection of separate problems. Type 2 diabetes. Obesity. Metabolic dysfunction–associated steatotic liver disease (MASLD, formerly NAFLD). High blood pressure. Heart disease. Early cognitive decline. Each one has its own specialist. That silo model is useful when an organ is failing. It is a poor map of how the illness started.

The unifying driver I call the source code is insulin resistance, together with the high insulin levels that come with it. The pancreas makes insulin. After a meal, especially one rich in refined carbohydrate, blood glucose rises. Insulin acts like a key. It tells muscle, liver, and fat cells to take glucose in and either burn it or store it. When the system is healthy, energy stays available, and blood sugar stays in a tight range.

The modern food pattern—ultra-processed products, sugar-sweetened drinks, and refined starch—knocks on that door all day. Cells eventually answer less well. Glucose lingers in the blood. Thepancreas’ss only immediate reply is to make more insulin. That combination, hyperglycemia plus hyperinsulinemia, is the hallmark of insulin resistance. It can run for ten or twenty years while a fasting glucose still looks “fine” on a routine checkup. The disease is already underway. The diagnosis has not been named yet.

From Hyperinsulinemia to System-Wide Breakdown

The journey from insulin resistance to a full-blown chronic disease diagnosis is often a long and silent one, spanning decades. During this time, persistently high insulin levels not only fail to manage blood sugar effectively; they also actively promote disease throughout the body.

The Long Road to Type 2 Diabetes

Type 2 diabetes is the most familiar ending of this story, not the beginning. For years, the pancreas compensates. Blood sugar stays in the normal or prediabetes range only because insulin is running high. Beta cells eventually fatigue. When they can no longer outrun the resistance, glucose climbs,s and the diagnosis is made. Treating only the late glucose number without asking why insulin had to work that hard is mopping the floor while the faucet runs.

The Liver’s Cry for Help: MASLD and MASH

The liver is central to fuel handling and highly sensitive to insulin. Healthy insulin tells the liver to stop making new glucose and to store surplus carbohydrate as glycogen. In resistance, the liver keeps pouring glucose into the blood even when levels are already high. At the same time, surplus carbohydrate—especially fructose—is converted into new fat through de novo lipogenesis. Fat cells that are themselves insulin resistant take up that fat poorly, so triglycerides pack inside hepatocytes.

That is MASLD. If inflammation and cell injury follow, the condition becomes MASH (formerly NASH), with fibrosis that can progress toward cirrhosis and liver failure. This pathway is driven by metabolic chaos, not by alcohol, in a large share of the patients we see. Global estimates have placed fatty liver in roughly a third of adults. On the border, where diabetes already runs above the national average, we treat this as a local public-health problem, not a rare specialty finding.

The Cardiovascular Connection

Insulin resistance is a primary driver of atherosclerosis. Hyperinsulinemia pushes an atherogenic lipid pattern: more VLDL and triglycerides, lower HDL, and small dense LDL particles that enter the arterial wall more easily. The kidneys retain sodium and water, raising blood volume. The endothelium makes less nitric oxide, so arteries stiffen. Chronic high insulin is also pro-inflammatory and makes vessel walls “sticky.”

High blood pressure, high triglycerides, low HDL, and abdominal obesity are not four unrelated problems. They are metabolic syndrome—the clinical signpost pointing back to the same source code.

The Brain and The Energy Crisis

The brain is an energy-hungry organ. When neurons become insulin resistant, they struggle to use glucose. That energy gap, together with inflammation and impaired cellular cleanup, is now tightly linked to later cognitive decline. Some clinicians call this pattern “type 3 diabetes.” The label is informal. The connection is not. Midlife metabolic health is brain health decades later.

National data make the scale hard to ignore. Measured NHANES figures from August 2021 through August 2023 show that 40.3% of U.S. adults age 20 and older have obesity, and 9.7% have severe obesity. More than one in three U.S. adults has prediabetes. Combined with diagnosed diabetes, well over 100 million Americans sit on this spectrum. El Paso County diabetes prevalence has been reported around 15% or higher—above Texas and U.S. averages—so this is not an abstract national chart. It is the waiting room.

Retatrutide: A Pharmaceutical Earthquake Threatening the Status Quo

Every so often, a medicine appears that does more than nudge a lab value. It forces us to ask whether the old  “manage it forever” model is still the only honest option. Retatrutide, an investigational triple agonist from Eli Lilly, is in that category. It is not yet a lifestyle replacement, and it is not freely available to every patient who might benefit. It is, however, a proof of concept: insulin resistance and fatty liver can move, and they can move a lot.

The Incretin Revolution: From GLP-1 to a Triple-Agonist

Incretins are gut hormones released after a meal. GLP-1 and GIP amplify insulin only when glucose is high, which is why the class has a relatively low risk of hypoglycemia when used without insulin or sulfonylureas. GLP-1 also slows gastric emptying, lowers glucagon, and reduces appetite in the brain.

GLP-1 receptor agonists such as semaglutide and liraglutide changed diabetes and obesity care. Dual agonists such as tirzepatide add GIP and produce even larger effects on weight and glucose. Retatrutide adds a third lever: the glucagon receptor. Activating glucagon alone would raise blood sugar. In combination with GLP-1 and GIP, glucagon-receptor activity appears to increase energy expenditure and hepatic fat oxidation. The liver’s metabolic engine is turned up, not just the appetite signal turned down.

What The Trials Actually Show

In a U.S. phase 2 trial in type 2 diabetes published in The Lancet, once-weekly retatrutide lowered HbA1c by about 2.0% to 2.16% at higher doses, outperformed dulaglutide 1.5 mg on glycemic control at those doses, and reduced body weight by as much as about 17% at 36 weeks. Insulin-resistance markers improved: HOMA-IR fell by roughly 39% at the 12 mg dose in related analyses, fasting insulin dropped, and adiponectin rose. A meaningful share of participants reached near-normal HbA1c. That is disease modification, not a slightly better logbook.

In obesity without diabetes, a phase 2 New England Journal of Medicine trial reported mean weight loss of 22.8% at 8 mg and 24.2% at 12 mg at 48 weeks.

For the liver, a 2024 Nature Medicine phase 2a substudy in people with obesity and MASLD found relative liver-fat reductions of about 81% to 82% at 8 mg and 12 mg by 24 weeks. Normal liver fat (under 5%) was reached in 79% and 86% of participants at those doses, versus none on placebo. Liver-fat loss tracked with weight, abdominal fat, and improved insulin-sensitivity markers.

Those numbers do not justify the older claim that a third of patients instantly become “insulin independent” as a settled, stand-alone statistic. They do justify a stronger sentence: the biology is plastic. Fatty liver can empty. Insulin sensitivity can rise. Weight can move in a range once reserved for surgery.

Access, Price, and The Tension Between Reversing and Managing Disease

A medicine that can shrink the future need for lifelong insulin, blood-pressure stacks, and dedicated liver drugs collides with a system organized around long-term disease management. Incretin drugs have already exposed the weak points: list price, prior authorization, shortages, compounding disputes, and biologic exclusivity.

The public conversation talks about market size. The harder conversation is who gets the tool. Broad, affordable use across the tens of millions of Americans with metabolic syndrome would be a public-health win. Narrow use at a premium price among the well-insured is the path a reimbursement system knows how to walk. Patients should understand that tension without waiting on it. Nervous-system care, food, muscle, sleep, and medical supervision can start this week. A peptide, if and when it is appropriate, is one instrument in that orchestra—not the concert.

Chiropractic Care for Insulin Resistance and Metabolic Health

This is the section most metabolic articles skip, and it is the section that belongs at the center of an integrative practice.

A narrow view of chiropractic is “crack the back, ease the ache.” An integrative view is different. The spine houses and protects the nervous system—the master regulator of heart rate, digestion, hormone output, immune tone, breathing pattern, and the stress response. Insulin resistance is not only a pancreas-and-diet problem. It is also a problem of chronic sympathetic drive, poor sleep, limited movement, and a body that cannot switch into rest, digest, and repair.

Chiropractic care does not replace nutrition, resistance training, or medicine. Used well, it removes mechanical and neurologic interference so those other inputs can actually land. That is the clinical claim. Here is how it works, mechanism by mechanism.

1. Fight-or-Flight is a Metabolic State

The autonomic nervous system has two main branches. The sympathetic system is fight-or-flight. The parasympathetic system, largely via the vagus nerve, is rest-and-digest. A healthy metabolism needs both. It also needs to be able to switch.

Sustained sympathetic dominance raises cortisol and related stress hormones. Cortisol tells the liver to dump glucose into the blood as emergency fuel. It worsens insulin sensitivity in muscle. It favors central fat storage. A patient can “eat clean” on paper and still lose ground if the nervous system is locked on high alert.

Physical pain, joint restriction, forward-head posture, and a locked mid-back are not separate from that loop. They are stress. The brain keeps receiving threat signals from the joints and muscles. Cortisol and inflammatory tone stay up. Insulin has to work in a hostile environment.

A specific adjustment is a precise mechanical input meant to restore motion and reduce that afferent threat. Research on spinal manipulation and the autonomic nervous system remains mixed and often low quality. A 2024 systematic review found that manipulation did not consistently change any autonomic marker compared with sham. Still, there was a signal that cervical manipulation may influence high-frequency heart-rate variability, a parasympathetic marker. That is not a claim that an adjustment “cures diabetes.” It is a reason to take neck and upper-back function seriously in every metabolic patient.

2. Vagal Tone, The Upper Neck, and The Metabolic Brake

The vagus nerve exits the skull near the upper cervical spine and then innervates the heart, lungs, gut, liver, and pancreas. Higher vagal tone is associated with better heart-rate variability, a stronger cholinergic anti-inflammatory reflex, healthier gut motility, and more flexible glucose handling—including the cephalic-phase insulin response and hepatic glucose control.

This is where cranial-cervical work and upper-cervical specificity earn their place in a metabolic program. The atlas and axis sit next to brainstem autonomic centers. Restriction there will not be the sole cause of prediabetes. It is a crossroads: jaw mechanics, nasal breathing, head posture, sleep quality, and vagal pathways. Restoring motion in that region is one practical way we try to support parasympathetic recovery—especially in patients who clench, mouth-breathe, live in pain after a crash, or cannot stay asleep.

In clinic, we don’t stop at the adjustment. We pair it with habits that intentionally raise vagal tone: slow nasal breathing at about six breaths a minute, a longer exhale than inhale, a 10-minute walk after meals, and a low threshold for screening for sleep apnea rather than pretending an adjustment fixes every snore.

3. Pain Shuts the Glucose Sink. Movement Opens It.

Skeletal muscle is the body’s largest insulin-responsive tissue. It stores glucose as glycogen. When back pain, sciatica, neck injury, or knee pain shuts down training, those tanks stay full. The next meal has fewer places to put carbohydrate. The pancreas must push out more insulin.

This is the most under-taught chiropractic contribution to metabolic health: get the person moving again without flaring the injury.

El Paso personal-injury and VA patients make the point obvious. A person with a lumbar disc, delayed whiplash symptoms, or chronic sacroiliac pain will not “just start HIIT.” Specific adjustments, soft-tissue work, spinal decompression when indicated, and graded rehabilitation reduce the pain brake. Then we can load the hips, legs, and trunk—the tissues that dispose of glucose.

During and right after muscle contraction, GLUT4 transporters move to the cell surface and pull glucose in without insulin. That bypass is one of the best acute treatments for insulin resistance we have. Chiropractic care does not replace the squat, the carry, or the walk. It often makes them possible. A metabolic plan that ignores pain is a plan that will be abandoned by week three.

4. The Mid-Back, Ribs, Diaphragm, and Sleep

Thoracic restriction changes more than posture. A stiff thoracic spine and rib cage limit diaphragmatic excursion. Shallow chest breathing keeps the body closer to a sympathetic pattern. It also worsens reflux, bloating, and the sense of “I cannot get a full breath,” which then wrecks sleep.

Sleep loss itself induces insulin resistance in healthy adults after a single short night. Neck and thoracic care, airway-aware posture work, and referral for sleep-apnea evaluation are therefore metabolic interventions. Dr. Cardenas’s medical oversight matters here. We do not treat every snorer with an adjustment and call it finished. We look for medical sleep disorders and treat the mechanical contributors we can change.

The thoracic spine also sits near the sympathetic chain that talks to visceral organs. We do not claim that a T5 adjustment “resets the pancreas.” We do claim that restoring rib and thoracic motion, reducing pain-guarding, and improving breathing change the daily autonomic and inflammatory background in which insulin has to work.

5. Inflammation, Cortisol, and What the Biomarker Studies Actually Say

Chronic musculoskeletal pain is a physiologic stressor. Pain signals raise inflammatory cytokines and stress hormones, which feed insulin resistance. Taking away the biomechanical driver of that pain is not cosmetic. It is an anti-inflammatory strategy with a mechanical entry point.

Spinal manipulation can shift short-term biochemical markers—cortisol and certain cytokines—though results vary by study, spinal region, and whether the person is in pain. Reviews describe low-to-moderate quality evidence for immediate cortisol changes and some shifts in inflammatory markers. A 2025 pragmatic trial of 12 weeks of chiropractic care versus sham reported changes in BDNF, IL-6, TNF-?, and later cortisol and interferon-gamma patterns, consistent with a systemic physiologic effect, not only a local joint effect.

Read that carefully. These studies do not prove that an adjustment lowers fasting insulin the way metformin or an incretin drug can. They support a more modest, still useful idea: skilled spinal care is a neuromodulatory input. In a patient whose insulin resistance is being fed by pain, poor sleep, and sympathetic lock-in, that input belongs in the stack.

6. Gut–Brain–Spine: Why Digestion Belongs in a Chiropractic Metabolic Visit

The gut is not a side quest in insulin resistance. Dysbiosis and a leaky intestinal barrier drive systemic inflammation that worsens insulin signaling. The vagus nerve is a two-way cable between gut and brain. Motility, enzyme output, and the migrating motor complex all feel autonomic tone.

When we restore cervical and thoracic motion and coach breathing and meal timing, we are also trying to improve the neural climate for digestion. That is why a metabolic chiropractic visit in our clinic asks about bloating, reflux, constipation, and post-meal crashes—not only about the numeric pain score. Functional stool testing and nutrition work then have a nervous system that is not fighting them.

How we use chiropractic inside a metabolic program in El Paso

• Map the mechanical drivers: upper cervical and cranial-cervical mechanics, thoracic and rib restriction, lumbar and pelvic load, loss of hip extension, forward-head posture, and gait changes after a crash or work injury.
• Adjust with a purpose. Restore motion where the nervous system and respiration are taxed. Do not “pop everything.”
• Rehabilitate on the same day whenever possible. Anti-rotation core work, hip hinges, loaded carries, and walking programs are glucose-disposal tools, not afterthoughts.
• Treat the injury and the metabolism together. Personal-injury and VA patients often arrive with delayed symptoms, sleep disruption, and weight gain from inactivity. Waiting until “the case is over” to talk about insulin is how prediabetes becomes diabetes.
• Coordinate medically. Dr. Cardenas reviews medications, secondary causes of weight gain, thyroid and sleep issues, and whether a patient qualifies for nutrition-only care, supervised carbohydrate reduction, or, when appropriate, incretin-based therapy.

Chiropractic care is the foundation layer—not because it replaces food or medicine, but because a dysregulated, painful nervous system will sabotage both.

Transform Your Body!- Video

Functional Medicine: Asking Why This Person Became Insulin Resistant

If chiropractic restores the control system, functional medicine asks why this particular person lost metabolic flexibility. The diagnosis of “prediabetes” is not an explanation. It is a late headline.

What we measure beyond a fasting glucose

• Fasting insulin and C-peptide, not only glucose and HbA1c. “Normal” glucose with high insulin is not healthy. It is compensation.
• Inflammation: hs-CRP and, when indicated, a broader cytokine or homocysteine picture.
• An advanced lipid panel that looks at particle size and number, not only total cholesterol.
• Nutrients that insulin signaling actually uses: vitamin D, magnesium, and others as indicated.
• Gut function when the history points there: stool testing, not a generic probiotic guess.
• HPA-axis rhythm when stress and sleep are the dominant story: cortisol patterning rather than a single morning draw.
• Toxin and endocrine-disruptor history when occupation, plastics exposure, or unexplained resistance to standard care suggests it.

The 5R frame we use with patients

• Remove what is in the way: ultra-processed food, sugar-sweetened drinks, hidden food triggers, untreated sleep apnea, and avoidable toxic load.
• Replace what is missing: protein at meals, fiber, micronutrients, and digestive support when needed.
• Reinoculate the gut with food first and targeted probiotics when testing or history supports them.
• Repair the barrier and tissue with sleep, amino acids, and reduced inflammatory drive.
• Rebalance the daily rhythm: meal timing, strength training, walking after meals, and nervous-system work so cortisol is not running the glucose show at 2 a.m.

Nutrition and training that lower insulin without waiting on a prescription

The most direct way to lower insulin is to lower the main stimulus for its release. We move patients off the borderland default of refined flour and sweetened drinks and toward whole-food protein, produce, and fats. For some, a structured period of lower carbohydrate intake—sometimes into nutritional ketosis—breaks the hyperinsulinemia cycle. Insulin falls. Fat cells can release stored energy. Ketones, especially beta-hydroxybutyrate, act as signaling molecules that can quiet inflammatory pathways. This is not a forever internet template. We individualize, and we monitor. Patients on insulin or sulfonylureas need medical supervision because doses often must come down as sensitivity returns.

Time-restricted eating is an eating pattern, not a religion. A 12-hour overnight fast is a start. Fourteen-to-ten or sixteen-to-eight can follow if sleep, training, and medications allow. Longer fasts are not first-line in frail, underweight, pregnant, or highly stressed patients.

Resistance training and intervals empty glycogen and grow mitochondria. We program to the person in front of us. A veteran with lumbar stenosis does not get the same plan as a weekend athlete. Consistency beats an intensity that puts them back on the table.

One Patient, One Plan: What Integration Looks Like

Imagine a 55-year-old El Paso patient with type 2 diabetes, high blood pressure, fatty liver, excess weight, chronic low-back pain, poor sleep, and a job that keeps him seated. A fragmented system hands him metformin, a blood-pressure pill, a statin, and a physical-therapy referral. Four charts. Little conversation among them.

In our setting,g the plan is one document.

Medical oversight (Dr. Cardenas). Confirm diagnoses, review labs, manage prescriptions, screen for sleep apnea and secondary causes, and decide whether an incretin medicine is appropriate as a bridge while rebuilding the foundation.

Chiropractic and rehabilitation (Dr. Jimenez). Correct upper-cervical and thoracic restrictions that keep him in fight-or-flight. Unload the painful lumbar segments. Restore hip extension. Get him walking and lifting without a flare so muscle can start acting like a glucose sink again.

Functional workup. Fasting insulin, not only glucose. Gut and nutrient gaps. A food pattern he can keep in this city, with this family, on this budget.

A single follow-up rhythm. As pain falls and insulin sensitivity rises, medications are not a life sentence by default. They are tools we try to need less of. That is the opposite of managed decline.

A molecule like retatrutide, if it becomes available and appropriate for that patient, can put out the fire faster. The nervous system, the gut, the plate, and the barbell decide whether the fire stays out.

A Vision for Metabolic Health in El Paso

The science is no longer vague. Insulin resistance is a common root. Medicines in the incretin family show how far biology can go when you treat that root. The same biology responds—more slowly, more cheaply, and with fewer access barriers—to food, muscle, sleep, and a nervous system that can leave fight-or-flight.

That is why I trained across chiropractic, advanced practice nursing, and functional medicine. The spine is not a side chapel next to the metabolic cathedral. It is part of the same building. When we restore motion, lower pain-driven cortisol, open the muscle sink, and improve vagal and breathing mechanics, we are doing metabolic work. When Dr. Cardenas adds medical diagnosis and, when needed, pharmacologic force, we are not abandoning that work. We are completing it.

You already own the biology. The conversation about your insulin, your spine, and your future should happen on your terms—not only after a lab crosses an arbitrary line.

References

1. Centers for Disease Control and Prevention / National Center for Health Statistics. (2024–2026). Adult obesity and overweight prevalence, NHANES August 2021–August 2023. www.cdc.gov/nchs/fastats/obesity-overweight.htm
2. Centers for Disease Control and Prevention. Prediabetes and National Diabetes Statistics resources. www.cdc.gov/diabetes
3. El Paso Center for Diabetes. Local diabetes prevalence notes for El Paso County versus Texas and U.S. averages. epdiabetes.org/resources
4. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. doi.org/10.1056/NEJMoa2301972
5. Rosenstock, J., Frias, J., Jastreboff, A. M., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized phase 2 trial. The Lancet, 402(10401), 529–544. doi.org/10.1016/S0140-6736(23)01053-X
6. Sanyal, A. J., et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30, 2037–2048. doi.org/10.1038/s41591-024-03018-2
7. Rosenstock, J., et al. (2024). Retatrutide improves markers of pancreatic beta-cell function and insulin sensitivity (266-OR). Diabetes, 73(Suppl. 1). doi.org/10.2337/db24-266-OR
8. Srikesavan, C., et al. (2024). Effectiveness of spinal manipulation in influencing the autonomic nervous system: a systematic review and meta-analysis. Journal of Manual & Manipulative Therapy, 32(1). doi.org/10.1080/10669817.2023.2285196
9. Haas, A., et al. (2024). Vertebral subluxation and systems biology: An integrative review. Cureus, 16(3), e56223. doi.org/10.7759/cureus.56223
10. Amjad, I., et al. (2025). The effects of 12 weeks of chiropractic spinal adjustments on physiological biomarkers in adults: A pragmatic randomized controlled trial. PLOS ONE. doi.org/10.1371/journal.pone.0338730
11. Kovanur-Sampath, K., et al. Systematic reviews on spinal manipulation and biochemical markers (cortisol, cytokines), 2017–2024.

SEO Tags: insulin resistance, retatrutide, metabolic syndrome, integrative medicine, chiropractic care, functional medicine, Dr. Alex Jimenez, El Paso, type 2 diabetes, NAFLD, NASH, obesity, prevention, hyperinsulinemia, GLP-1, triple-agonist, Dr. Maria Cardenas, cardiovascular disease, upstream medicine, root cause, autonomic nervous system, vertebral subluxation, personalized healthcare, chronic disease, health and wellness